Substituted porphyrins

• US 8,546,562 B2
• Filed: 04/26/2012
• Issued: 10/01/2013
• Est. Priority Date: 01/25/1999
• Status: Expired due to Fees

• Current Assignee: Duke University, National Jewish Health
• Original Assignee: National Jewish Health
• Inventors: Crapo, James D., Day, Brian J., Trova, Michael P., Gauuan, Polvina Jolicia F., Kitchen, Douglas B., Fridovich, Irwin, Batinic-Haberle, Ines
• Primary Examiner(s): Ward, Paul V.
• Application Number:
  US13/457,232
• Publication Number:
  US 20120214780A1
• Time in Patent Office: 523 Days
• Field of Search: 540/145, 514/185, 514/410
• US Class Current: 540/145
• CPC Class Codes: A61K 31/409 having four such rings, e.g. porphine derivatives, bilirubin, biliverdine hemin, hematin A61K31/555
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 487/22 in which the condensed system contains four or more hetero rings
• CPC Class Codes: C09B 47/00 Porphines; Azaporphines non-dyeing compounds C07D487/22

Abstract

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

Claims

1. A method of treating an ischemia reperfusion injury, said method comprising administering to a subject in need thereof an effective amount of a compound of formula

2. The method according to claim 1, wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

3. The method according to claim 2, wherein said compound is

4. A method of treating a neurologic disorder, said method comprising administering to a subject in need thereof an effective amount of a compound of formula

5. The method according to claim 4, wherein said neurologic disorder is associated with an over stimulation of an NMDA subtype of a glutamate receptor.

6. The method according to claim 5, wherein said compound inhibits NMDA induced injury.

7. The method according to claim 4, wherein said neurologic disorder is Parkinson'"'"'s disease.

8. The method according to claim 4, wherein said neurologic disorder is ALS.

9. The method according to claim 4, wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

10. The method according to claim 9, wherein said compound is complexed with manganese.

11. The method according to claim 10, wherein said compound is